ArticleFrontiers in endocrinology2025
Efficacy and safety of prophylactic intravenous calcium supplementation in patients with secondary hyperparathyroidism after parathyroidectomy: a retrospective study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Severe hypocalcemia is a common complication in patients with secondary hyperparathyroidism (SHPT) after parathyroidectomy (PTX). The necessity of postoperative prophylactic intravenous calcium supplementation and the corresponding strategies are controversial. This study aimed to analyze the efficacy and safety of prophylactic intravenous calcium supplementation after PTX. Methods: We retrospectively reviewed the clinical data of 125 patients with SHPT who underwent PTX between January 2020 and December 2023. Patients were divided into prophylactic intravenous calcium supplementation group (group A, 94 cases) and non-prophylactic intravenous calcium supplementation (group B, 31 cases). The baseline characteristics, laboratory data, surgical outcomes of the two groups were compared. Binary logistic regression analysis was used to identify risk factors for severe hypocalcemia and hypercalcemia after calcium supplementation. Results: The incidence of severe hypocalcemia in group A (30 cases, 31.9%) was lower than that in group B (19 cases, 61.3%) (P = 0.004). Binary logistic regression analysis revealed that non-prophylactic intravenous calcium supplementation, high level of preoperative parathyroid hormone (PTH) and alkaline phosphatase (ALP), and low level of preoperative serum calcium were risk factors for severe hypocalcemia. Preoperative high level of ALP was a negative predictor for hypercalcemia after calcium supplementation. Conclusions: Postoperative prophylactic intravenous calcium supplementation, followed by dynamic dosage adjustments based on serum calcium levels, in addition to routine oral calcium and calcitriol supplementation, could significantly reduce the incidence of severe hypocalcemia without substantially increasing the risk of hypercalcemia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.